Free Trial

COMPASS Pathways Q1 2024 Earnings Report

COMPASS Pathways logo
$4.21 -0.33 (-7.27%)
As of 02/21/2025 04:00 PM Eastern

COMPASS Pathways EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.52
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

COMPASS Pathways Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

COMPASS Pathways Announcement Details

Quarter
Q1 2024
Time
N/A

CMPS Upcoming Earnings

COMPASS Pathways will be holding an earnings conference call on Thursday, February 27 at 8:00 AM Eastern. Interested parties can register for or listen to the call.

Conference Call Resources

Conference Call Audio

COMPASS Pathways Earnings Headlines

Market down? Do this now.
During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.
HC Wainwright Lifts Earnings Estimates for COMPASS Pathways
HC Wainwright Has Bearish Estimate for CMPS FY2028 Earnings
Compass Pathways price target lowered to $45 from $60 at H.C. Wainwright
See More COMPASS Pathways Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like COMPASS Pathways? Sign up for Earnings360's daily newsletter to receive timely earnings updates on COMPASS Pathways and other key companies, straight to your email.

About COMPASS Pathways

COMPASS Pathways (NASDAQ:CMPS) operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

View COMPASS Pathways Profile

More Earnings Resources from MarketBeat